Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACEPHEN vs DRONABINOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Partial agonist at cannabinoid receptors CB1 and CB2; mimics endogenous cannabinoids, inhibiting adenylate cyclase and modulating neurotransmitter release (e.g., GABA, glutamate).
Mild to moderate pain,Fever
Nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond to conventional antiemetics,Anorexia associated with weight loss in patients with AIDS
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
2.5-10 mg orally twice daily, titrated to effect; maximum 15 mg per day in divided doses.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Terminal elimination half-life is approximately 25–36 hours in chronic users due to extensive tissue distribution and slow release from fat stores; in naive users, half-life is shorter, around 20–30 hours. The prolonged half-life contributes to accumulation with repeated dosing.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Hepatic via CYP2C9 and CYP3A4; major metabolite 11-hydroxy-dronabinol (active); further oxidation to 11-nor-9-carboxy-dronabinol.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Primarily hepatic metabolism followed by biliary and fecal excretion. Approximately 65% eliminated in feces and 35% in urine, mostly as metabolites. Less than 5% of unchanged drug is excreted in urine.
Approximately 10-20% bound to serum albumin; extensive tissue binding.
Highly protein-bound: >95% bound primarily to albumin and, to a lesser extent, lipoproteins.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Extremely large, estimated at 10–30 L/kg due to high lipophilicity and extensive tissue uptake, particularly into adipose tissue and brain. This accounts for the slow elimination and prolonged action.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
Oral bioavailability is low and variable, approximately 10–20% due to extensive first-pass hepatic metabolism. There is significant interindividual variability based on metabolism and formulation.
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
No dosage adjustment necessary for GFR >30 m L/min; insufficient data for GFR <30 m L/min, use with caution.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
Child-Pugh A: no adjustment; Child-Pugh B: reduce starting dose to 1.25-2.5 mg twice daily and titrate cautiously; Child-Pugh C: avoid use.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
Not recommended for use in children under 18 years due to lack of safety and efficacy data.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Initiate at 1.25-2.5 mg twice daily; monitor for CNS effects and falls; titrate slowly.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
None
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Central nervous system depression (e.g., dizziness, drowsiness, impaired coordination),Paradoxical reactions (e.g., increased nausea, vomiting),Risk of abuse and dependence due to psychoactive effects,Cardiovascular effects (e.g., tachycardia, hypotension),May cause seizures in patients with history of epilepsy,Not recommended for chemotherapy-induced nausea in patients receiving concomitant central nervous system depressants
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
Hypersensitivity to dronabinol or any component of the formulation,History of hypersensitivity to marijuana or cannabinoids,Breastfeeding (due to potential infant exposure)
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
High-fat meals may increase absorption; take consistently with respect to meals. Avoid grapefruit juice as it may increase dronabinol levels.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
Dronabinol is a synthetic cannabinoid. Data on human pregnancy are limited. Animal studies show developmental toxicity at high doses. First trimester: potential risk of fetal abnormalities cannot be excluded; avoid unless benefit outweighs risk. Second and third trimesters: may cause fetal neurobehavioral effects; use only if clearly needed. Late pregnancy: associated with neonatal withdrawal symptoms and possible long-term neurodevelopmental effects.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Dronabinol is excreted into breast milk. The milk-to-plasma ratio (M/P) is not established but cannabinoids are highly lipophilic and concentrate in milk. Effects on the nursing infant are unknown; however, potential for adverse effects on neurodevelopment exists. Breastfeeding is not recommended during dronabinol therapy.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
Pregnancy may alter dronabinol pharmacokinetics (increased volume of distribution, altered hepatic metabolism), but specific dose adjustments are not established. Use the lowest effective dose for the shortest duration. Monitor for increased adverse effects from altered metabolism. Avoid use in pregnancy unless potential benefit justifies potential risk to the fetus.
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Dronabinol is synthetic THC, used for chemotherapy-induced nausea and vomiting (CINV) and appetite stimulation in AIDS wasting. Onset is 0.5-1 hour orally; titrate slowly due to psychoactive effects. May cause euphoria, dizziness, and cognitive impairment. Use with caution in patients with psychiatric disorders, seizure disorders, or history of substance abuse. Monitor for hypotension and tachycardia. Avoid concurrent use with other CNS depressants.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
Take exactly as prescribed; do not increase dose or frequency.,Avoid driving or operating heavy machinery until you know how this medication affects you.,This drug may cause dizziness, drowsiness, or confusion; avoid alcohol and other CNS depressants.,Report any mood changes, hallucinations, or unusual thoughts to your healthcare provider.,Keep out of reach of children and store in a cool, dry place.,For nausea, take at least 1 hour before chemotherapy (if used as prophylaxis).,For appetite stimulation, take before meals.
No interactions on record
"Ethotoin, a hydantoin anticonvulsant, potentiates the central nervous system (CNS) depressant effects of dronabinol, a cannabinoid used for nausea and appetite stimulation. This additive CNS depression can lead to excessive sedation, dizziness, ataxia, and impaired cognitive and motor function. Clinically, patients may experience increased risk of falls, respiratory depression at high doses, and reduced ability to perform tasks requiring alertness."
"Nabilone, a synthetic cannabinoid agonist, and dronabinol, a synthetic delta-9-tetrahydrocannabinol, both exert central nervous system (CNS) depressant effects via activation of cannabinoid receptors (CB1) in the brain. Concurrent use leads to additive or synergistic CNS depression, resulting in enhanced sedation, dizziness, ataxia, and impairment of cognitive and motor function. Clinically, this may manifest as excessive drowsiness, confusion, or impaired coordination, increasing the risk of falls or accidents, especially in elderly or debilitated patients."
"Thiothixene, a typical antipsychotic with significant antidopaminergic and alpha-adrenergic blocking properties, may potentiate the central nervous system (CNS) depressant effects of dronabinol, a cannabinoid used for appetite stimulation and antiemesis. This additive CNS depression can lead to excessive sedation, dizziness, psychomotor impairment, and increased risk of falls or cognitive dysfunction. Clinically, patients may experience heightened somnolence, ataxia, or orthostatic hypotension, particularly during initiation or dose titration of either agent."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACEPHEN vs DRONABINOL, answered by our medical review team.
ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. DRONABINOL is a Cannabinoid that works by Partial agonist at cannabinoid receptors CB1 and CB2; mimics endogenous cannabinoids, inhibiting adenylate cyclase and modulating neurotransmitter release (e.g., GABA, glutamate).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACEPHEN and DRONABINOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. The standard adult dose of DRONABINOL is: 2.5-10 mg orally twice daily, titrated to effect; maximum 15 mg per day in divided doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACEPHEN and DRONABINOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. DRONABINOL is classified as Category D/X. Dronabinol is a synthetic cannabinoid. Data on human pregnancy are limited. Animal studies show developmental toxicity at high doses. First trimester: potential risk of fetal abnor. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.